Phosphodiesterase IV inhibitors for kidney and ureter disease treatment - with eg (4-(3-(cyclopentyl oxy) 4-methoxyphenyl-2-pyrrolidinone) being specific for kidney and ureter tissue relaxation

摘要

Use of inhibitors of phosphodiesterase (PDE) IV for the treatment of kidney and ureter diseases is new. Also claimed is the use of e.g, denbufylline (1,3-dibutyl-3,7- dihydro-7- (2-oxopropyl)- 1H-purine-2,6-dion), Ro 20-1724 (4-(3-butoxy-4- methoxyphenyl) methyl)-2- imidazolidinone), Rolipram (4-(3-(cyclopentyloxy) 4-methoxyphenyl)- 2-pyrrolidinone), Tibenelast (5,6-diethoxy benzo(b)thiophen-2-carbonic acid) or their physiologically acceptable salts in this treatment. Parenteral applications contain 0.5microg to 2mg, pref. 5 to 500microg of the component. ADVANTAGE - Current treatment of e.g, colics of the ureter involves the admin. of painkillers without treating the cause of the disease. The new medicaments treat the cause of colics of the ureter and kidney.